|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2017-12-14 |
|
|
|
|
|
|
最高研发阶段临床2期 |
首次获批国家/地区- |
首次获批日期- |
Efficacy and Safety of Combination EMB-001 as a Potential Smoking Cessation Treatment
EMB-001 is a combination of 2 drugs: the cortisol synthesis inhibitor, metyrapone (Metopirone®), and the benzodiazepine receptor agonist, oxazepam (original trade name Serax®; now marketed as oxazepam (generic) only).
This is an open-label study in up to 50 adult subjects to help smokers abstain from smoking during a 12-week trial period.
Efficacy and Safety of Combination EMB-001 as a Potential Smoking Cessation Treatment
This open-label study will evaluate EMB-001, comprised of metyrapone, a cortisol synthesis inhibitor marketed as a diagnostic drug for testing hypothalamic-pituitary-adrenal (HPA) axis function, combined with oxazepam, an anxiolytic and sedative/hypnotic benzodiazepine, to help smokers abstain from smoking during a 12-week trial period.
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Safety and Efficacy of EMB 001 in Subjects With Moderate-to-Severe Cocaine Use Disorder
EMB-001 is a combination of 2 drugs: the cortisol synthesis inhibitor, metyrapone (Metopirone®), and the benzodiazepine receptor agonist, oxazepam (original trade name Serax®; now marketed as oxazepam (generic) only).
This is a Phase 2 study in approximately 80 adult subjects with moderate-to-severe Cocaine Use Disorder (CUD).
100 项与 Embera NeuroTherapeutics, Inc. 相关的临床结果
0 项与 Embera NeuroTherapeutics, Inc. 相关的专利(医药)
100 项与 Embera NeuroTherapeutics, Inc. 相关的药物交易
100 项与 Embera NeuroTherapeutics, Inc. 相关的转化医学